...s children below the age of three are underweight ... bed hungry every day, says new data.// The Natio... Food Programme (WFP) say 45.9 percent of Indian c...erweight - they do not meet the standard weight in...
...r are quite frustrated by the large number of stra...cases// recorded by the main SMHS hospital here la...the last two months. 'The situation is alarming. W...y day. In some cases the victims are suspected to ...
...a pronounced risk of suffering weak bones due to t... Therefore, physicians need to be vigilant to spot...ording to the report the mix of sedentary behavior...allout of cancer, could result in suppression of b...
...CORT? for asthma provides a rapid and clinically s...t// in lung function within 15 minutes after admin...that in comparison to its monocomponents (budesoni...ORT and the other treatment groups containing form...
Other Medicine News:Health News:Bone Fragility, a Risk for Children With Cancer 2Health News:New Data Shows Significant Asthma Control With Symbicort 2(Date:7/3/2009)... , TURKU, Finland, July 3 B...ent company with its headquarters in Turku, Finlan...clinical trial of ProtoCure(TM),emulsion cream, t...his,double-blind, placebo-controlled study, condu...o moderate atopic dermatitis who applied the Proto...
(Date:7/1/2009)... , REYKJAVIK, Iceland, July 1 /PRNewswire-F... schizophrenia ever undertaken has revealed severa...ce of the human genome (SNPs) linked to,risk of t...um of scientists,led by a team from deCODE geneti... than 50,000 patients and control participants fro...
(Date:6/30/2009)... , SAN DIEGO, June 30 Accumetri... mark (1,600 patients) in the enrollment of its la...nsiveness with A V erifyNow(R) Assay I mpact on ...ically designed to demonstrate the value of provid...ients who are poor responders to clopidogrel (Plav...
(Date:6/29/2009)... , Prospective Study Seeks to Assess RSV Burden...Reinforcing Commitment to Pediatric Research , ...Immune continues to advance its commitment to pedi...rst observational prospective study designed to as...V) among preterm infants 32-to-35 weeks gestationa...
Breaking Medicine Technology:BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis 2deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 2deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 3deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 4deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 5Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled 2MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants 2Exjade 28R 29 Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs According to Landmark Trial 31624 1Exjade 28R 29 Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs According to Landmark Trial 31624 2Exjade 28R 29 Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs According to Landmark Trial 31624 3Exjade 28R 29 Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs According to Landmark Trial 31624 4Exjade 28R 29 Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs According to Landmark Trial 31624 5Exjade 28R 29 Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs According to Landmark Trial 31624 6Exjade 28R 29 Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs According to Landmark Trial 31624 7Exjade 28R 29 Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs According to Landmark Trial 31624 8Exjade 28R 29 Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs According to Landmark Trial 31624 9Align Technology Receives Expanded Regulatory Approval in Japan 9567 1Align Technology Receives Expanded Regulatory Approval in Japan 9567 2Quantros Acquires MEDMARX 28R 29 from United States Pharmacopeia 28USP 29 9565 1Quantros Acquires MEDMARX 28R 29 from United States Pharmacopeia 28USP 29 9565 2Quantros Acquires MEDMARX 28R 29 from United States Pharmacopeia 28USP 29 9565 3Quantros Acquires MEDMARX 28R 29 from United States Pharmacopeia 28USP 29 9565 4AstraZeneca and Targacept Announce Top Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia 3593 1AstraZeneca and Targacept Announce Top Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia 3593 2AstraZeneca and Targacept Announce Top Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia 3593 3AstraZeneca and Targacept Announce Top Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia 3593 4... - Neurologix, Inc.,(OTCBB:NRGX) today announced t... The Lancet of positive results from the first eve...he first report of,direct gene transfer into a pat...tive disease., The open label Phase 1 study, condu...ase demonstrated both a lack of adverse,events rel...
...- The,PromegaExpress(TM) on-site stocking program ...ne of on-site appliances. This,latest addition ser...ry requirements for smaller areas when space is at...ols is a necessity. The,mid-sized cabinet can also... freezer component., The entire line (see attached...
Other Medicine Technology:Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 2Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 3Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 4Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 5Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 6The CYPHER Sirolimus-eluting Coronary Stent consists of a proven antiproliferative drug, called "sirolimus", a controlled-release polymer, and a closed-cell stent delivery platform. Upon placement, s
The eNclose Anastomosis Assist Device was designed specifically to obviate the need for partial clamping of the aorta. The enclose device can provide the surgeon with a stable, bloodless field and im
15mm Open Blades, 30mm Maximum Blade Spread; in Titanium.
7mm Cross Hairs; Available in 4.5mm to 7.0mm in 0.5mm increments; Ring depth available from 2 to 4mm in 0.5mm increments.; in stainless steel.
Medicine Products: